Janus Henderson Group PLC purchased a new position in shares of InnovAge Holding Corp. (NASDAQ:INNV - Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 121,117 shares of the company's stock, valued at approximately $971,000. Janus Henderson Group PLC owned approximately 0.09% of InnovAge at the end of the most recent reporting period.
A number of other institutional investors have also modified their holdings of INNV. T. Rowe Price Investment Management Inc. lifted its stake in shares of InnovAge by 10.3% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,168,330 shares of the company's stock valued at $32,014,000 after buying an additional 577,558 shares during the period. Hillsdale Investment Management Inc. acquired a new position in InnovAge in the 1st quarter valued at $4,250,000. Arrowstreet Capital Limited Partnership acquired a new position in InnovAge in the 1st quarter valued at $3,349,000. Marshall Wace LLP acquired a new position in InnovAge in the 4th quarter valued at $1,512,000. Finally, O Shaughnessy Asset Management LLC lifted its stake in shares of InnovAge by 1,978.3% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 238,881 shares of the company's stock worth $1,240,000 after purchasing an additional 227,387 shares during the period. Institutional investors and hedge funds own 12.26% of the company's stock.
InnovAge Price Performance
INNV opened at $10.90 on Tuesday. InnovAge Holding Corp. has a 52-week low of $3.17 and a 52-week high of $12.64. The company has a 50 day moving average of $10.45 and a two-hundred day moving average of $8.77. The company has a market cap of $1.48 billion, a P/E ratio of -121.11 and a beta of 0.39. The company has a quick ratio of 1.03, a current ratio of 1.03 and a debt-to-equity ratio of 0.26.
Analyst Ratings Changes
Several research firms recently weighed in on INNV. Weiss Ratings downgraded InnovAge from a "hold (c-)" rating to a "sell (d-)" rating in a research report on Monday, May 18th. Wall Street Zen cut InnovAge from a "buy" rating to a "hold" rating in a report on Sunday, May 17th. Finally, Zacks Research downgraded shares of InnovAge from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 24th. One analyst has rated the stock with a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Sell" and an average price target of $7.00.
View Our Latest Stock Report on InnovAge
InnovAge Profile
(
Free Report)
InnovAge Holdings, Inc NASDAQ: INNV is a healthcare services company that specializes in caring for seniors through the Program of All-Inclusive Care for the Elderly (PACE). Designed for individuals who are eligible for both Medicare and Medicaid, the PACE model integrates medical care, social services and long-term care—delivered primarily in participants' homes and community-based centers. InnovAge's approach centers on interdisciplinary care teams that coordinate everything from primary and specialty medical services to nutritional counseling and recreational activities.
The company's core offerings include comprehensive in-home assessments, physician and nursing services, physical and occupational therapy, prescription medication management, and transportation to medical appointments.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider InnovAge, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InnovAge wasn't on the list.
While InnovAge currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.